Drug

Investment of ₹5,210 cr made under PLI scheme for bulk drugs till Jun: Govt

The government has made wide-ranging efforts to increase investment in the pharmaceutical sector for enhancing manufacturing capabilities, to prevent disruption in supply of critical APIs

4 killed in strike on alleged drug-smuggling boat in Caribbean: US military

The US military attacked a boat suspected of being used to smuggle drugs in the Caribbean Sea, killing four people, as the Trump administration continues its monthslong campaign against alleged traffickers in Latin America. The attack on Saturday brings the number of people who have been killed in boat strikes by the US military to at least 231 in 69 strikes since the Trump administration began targeting those it calls "narcoterrorists" almost a year ago. As with most of the military's statements on strikes in the eastern Pacific Ocean and Caribbean Sea, US Southern Command said it targeted the alleged drug traffickers along known smuggling routes. The military did not provide evidence that the vessel was ferrying drugs. A video posted on X showed an image of what appeared to be a moving boat followed by a flash. The Trump administration is pursuing deals with allied nations to extend its offensive to land across multiple Latin American countries. Defence Secretary Pete Hegseth sa

CDSCO forms expert panel to regulate AI use in drug discovery: DCGI

DCGI Rajeev Raghuvanshi says the panel includes AI experts and will discuss how AI used in drug discovery should be evaluated, approved and regulated

Maha FDA inspects 2,902 drug establishments, acts against 880 licensees

Maharashtra FDA conducted 104 search and seizure operations between June and August, seizing illegal drugs and cosmetics worth Rs 11.41 crore and registering 20 FIRs

Novo outlook hike falls flat as Wegovy pill sales fail to impress

Novo Nordisk raised its 2026 outlook, but investor sentiment remained subdued as Wegovy pill sales disappointed and CagriSema faced another setback

Why Nestlé is changing its flavours because of weight-loss drugs

GLP-1 weight-loss drugs are changing more than just waistlines, they're changing how food tastes. And that's forcing food giant Nestlé to rethink its products.

Brazil rejects Dr Reddy's, Cipla GLP-1 generics on technical grounds

Brazil's regulator Anvisa rejects DRL and Cipla's generic GLP-1 drug filings, citing unmet technical requirements on efficacy, safety and quality

Trump orders faster review of psychedelic drugs including ibogaine

President Donald Trump on Saturday directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine, which recently has been embraced by combat veterans and conservative lawmakers despite having serious safety risks. Ibogaine and other psychedelics remain banned under the federal government's most restrictive category for illegal, high-risk drugs. But the administration is taking steps to ease restrictions and spur research on using the drugs for medical purposes, including conditions like severe depression. "Today's order will ensure that people suffering from debilitating symptoms might finally have a chance to reclaim their lives and lead a happier life," Trump said as he signed an executive order on the drugs. The Republican president said his directive will help "dramatically accelerate" access to potential treatments. "If these turn out to be as good as people are saying, it's going to have a tremendous impact," he said. Veteran organisations a

As generics wave builds up, Novo Nordisk slashes Ozempic, Wegovy prices

Drugmaker cuts prices of injectable semaglutide brands to expand access in India, but says no similar price reduction is planned for oral semaglutide brand Rybelsus

Effective oversight: Safety crucial for success of weight-loss drugs

According to the National Family Health Survey 2019-21, 24 per cent of Indian women and 23 per cent of Indian men are overweight

Zydus drug Desidustat for renal anaemia gets regulatory nod in China

Zydus Lifesciences on Saturday said its innovative drug has received approval from China's National Medical Products Administration (NMPA) for its drug Desidustat tablets used for treating renal anaemia. The company has licensed its Desidustat tablets to a subsidiary of China Medical System Holdings Ltd. CMS International Development and Management Ltd, a wholly-owned subsidiary of CMS, had obtained an exclusive license for the drug from Zydus in 2020. Desidustat tablets are administered orally for treating anaemia in Chronic Kidney Disease (CKD) patients. CKD involves the gradual loss of kidney function and eventually leads to kidney failure. "We are encouraged by the NMPA's approval for marketing the drug in China. Our life-changing discoveries are driven by a commitment to improving patient outcomes and enabling healthier, more fulfilled lives, globally," Zydus Lifesciences MD Sharvil P Patel said in a statement. The company is happy to partner with CMS and is confident that th

China approves first brain-computer interface product for commercial use

The firm is among a wave of Chinese startups building technologies that allow people to control computers or other electronic devices using only their minds

CDSCO allows immediate lab testing of drugs to speed up approvals

CDSCO will permit drugmakers to begin testing samples as soon as applications are filed, shifting detailed scrutiny to later stages to shorten approval timelines and ease compliance

Experimental blood thinner cuts risk of stroke recurrence by 26%: Bayer

Positive Phase III results for asundexian boost CEO Bill Anderson's turnaround push as company seeks regulatory approval

Centre mandates drug cos to submit post-approval changes for new drugs

Draft amendment seeks mandatory reporting of manufacturing and quality changes to drug regulator

Govt moves to curb cheap penicillin-based drug imports for 1 year

Centre imposes one-year minimum import price on key penicillin inputs to check Chinese dumping and protect domestic bulk drug manufacturing

US military strikes on alleged drug boats kill 5 in eastern Pacific

The US military said Thursday that it had conducted two more strikes against boats it said were smuggling drugs in the eastern Pacific Ocean, killing five people. US Southern Command posted on social media, Intelligence confirmed that the vessels were transiting along known narco-trafficking routes in the Eastern Pacific and were engaged in narco-trafficking operations, though it did not provide evidence. It posted videos of each boat speeding through water before being struck by an explosion. The military said three people in one vessel and two in the other were killed. The attacks brought the total number of known boat strikes to 28 while at least 104 people have been killed, according to numbers announced by the Trump administration. President Donald Trump has justified the attacks as a necessary escalation to stem the flow of drugs into the United States and asserted the US is engaged in an armed conflict with drug cartels. The administration is facing increasing scrutiny from

Biocon launches drugs for diabetes and obesity treatment in Netherlands

The Netherlands launch builds on Biocon's entry into the UK in February, where it received regulatory approval for liraglutide from the Medicines and Healthcare Products Regulatory Agency

Eli Lilly, Pfizer drugs added to China's first private insurance list

As China's aging population increases demand for therapies treating everything from cancer and diabetes to dementia, the inclusion of these drugs may ease the burden on state medical insurance

Healthify seeks more weight-loss drug partnerships after Novo Nordisk deal

The deal marks Healthify's first such partnership with a drugmaker, and it hopes similar agreements will boost its paid subscriber base